{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:26Z","timestamp":1793933186012,"version":"4.8.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed\/refractory acute myeloid leukemia (AML) were randomly assigned to guadecitabine or a preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity treatment with HMAs or low-dose cytarabine, or best supportive care (BSC). The primary end point was overall survival (OS). A total of 302 patients were randomly assigned to guadecitabine (n\u00a0= 148) or TC (n\u00a0= 154). Preselected TCs were low-intensity treatment (n\u00a0= 233 [77%; mainly HMAs]), high-intensity chemotherapy (n\u00a0= 63 [21%]), and BSC (n\u00a0= 6 [2%]). The median OS were 6.4 and 5.4\u00a0months for guadecitabine and TC, respectively (hazard ratio 0.88 [95% confidence interval, 0.67-1.14]; log-rank P\u00a0= .33). Survival benefit for guadecitabine was suggested in several prospective subgroups, including age &amp;lt;65 years, Eastern Cooperative Oncology Group performance status 0 to 1, refractory AML, and lower peripheral blood blasts \u226430%. Complete response (CR)\u00a0+ CR with partial hematologic recovery rates were 17% for guadecitabine vs 8% for TC (P\u00a0&amp;lt; .01); CR+CR with incomplete count recovery rates were 27% for guadecitabine vs 14% for TC (P\u00a0&amp;lt; .01). Safety was comparable for the 2 arms, but guadecitabine had a higher rate of grade \u22653 neutropenia (32% vs 17%; P\u00a0&amp;lt; .01). This study did not demonstrate an OS benefit for guadecitabine. Clinical response rates were higher for guadecitabine, with comparable safety to TC. There was an OS benefit for guadecitabine in several prespecified subgroups. This study was registered at www.clinicaltrials.gov as #NCT02920008.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012062","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T15:43:10Z","timestamp":1705506190000},"page":"2020-2029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Guadecitabine vs TC in relapsed\/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"first","affiliation":[{"name":"1Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine and the New York-Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-8191","authenticated-orcid":false,"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[{"name":"2Hospital Universitari i Polit\u00e8cnic La Fe, Instituto de Investigaci\u00f3n Sanitaria La Fe,Valencia, and CIBERONC C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9952","authenticated-orcid":false,"given":"Karen","family":"Yee","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"6Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Byrne","sequence":"additional","affiliation":[{"name":"7Department of Medicine, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Patkowska","sequence":"additional","affiliation":[{"name":"8Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"9Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[{"name":"10H\u00f4pital Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Moors","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"12Department of Medicine, The University of Chicago Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"13Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"14H\u00f4pital Saint-Louis, Assistance Publique H\u00f4pitaux de Paris and Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"16Department of Hematology, University of Fukui Hospital, Eiheiji-ch\u014d, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey L.","family":"O'Connell","sequence":"additional","affiliation":[{"name":"17Keck School of Medicine of USC, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hao","sequence":"additional","affiliation":[{"name":"18Astex Pharmaceuticals, Inc, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold N.","family":"Keer","sequence":"additional","affiliation":[{"name":"18Astex Pharmaceuticals, Inc, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azab","sequence":"additional","affiliation":[{"name":"18Astex Pharmaceuticals, Inc, Pleasanton, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"19Department of Internal Medicine, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"9","key":"2024042315203306700_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2024042315203306700_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients. The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"2024042315203306700_bib3","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024042315203306700_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","article-title":"Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukemia (VALOR): a randomized, controlled, double-blind, multinational, phase 3 study","volume":"16","author":"Ravandi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"2024042315203306700_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","article-title":"International randomized phase iii study of elacytarabine versus investigator choice in patients with acute myeloid leukemia","volume":"32","author":"Roboz","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024042315203306700_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT-3 ITD acute myeloid leukemia (QuANTUM-R): a multicenter, randomized. controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"2024042315203306700_bib7","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT-3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024042315203306700_bib8","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024042315203306700_bib9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2024042315203306700_bib10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"2024042315203306700_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"35","key":"2024042315203306700_bib12","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT-3 mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024042315203306700_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late stage mutant IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"De Botton","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024042315203306700_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2024042315203306700_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-134-7-200104030-00011","article-title":"Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications","volume":"134","author":"Santini","year":"2001","journal-title":"Ann Intern Med"},{"issue":"8","key":"2024042315203306700_bib16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","article-title":"SGI-110: DNA methyltransferase inhibitor oncolytic","volume":"38","author":"Griffiths","year":"2013","journal-title":"Drugs Future"},{"issue":"9","key":"2024042315203306700_bib17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024042315203306700_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.31138","article-title":"Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia","volume":"124","author":"Roboz","year":"2018","journal-title":"Cancer"},{"issue":"Supplement_1","key":"2024042315203306700_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1182\/blood-2019-131394","article-title":"Durable remission and long term survival in relapsed\/refractory AML patients treated with guadecitabine, median survival not reached for responders after long-term follow up from phase 2 study of 103 patients","volume":"134","author":"Griffiths","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2024042315203306700_bib20","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024042315203306700_bib21","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024042315203306700_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2024042315203306700_bib23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024042315203306700_bib24","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/blood.V77.9.1894.1894","article-title":"Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia","volume":"77","author":"Archimbaud","year":"1991","journal-title":"Blood"},{"issue":"1","key":"2024042315203306700_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","article-title":"Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia. Long-term follow up of the etoposide, mitoxantrone, and cytarabine-86 trial","volume":"13","author":"Archimbaud","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024042315203306700_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2001.02551.x","article-title":"A\u00a0multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine, and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation","volume":"112","author":"Jackson","year":"2001","journal-title":"Br J Haematol"},{"issue":"17","key":"2024042315203306700_bib27","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/bloodadvances.2023010179","article-title":"Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024042315203306700_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13148-019-0704-3","article-title":"Genomic and epigenomic predictors of response to guadecitabine in relapsed\/refractory acute myelogenous leukemia","volume":"11","author":"Chung","year":"2019","journal-title":"Clin Epigenetics"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/2020\/2222788\/blooda_adv-2023-012062-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/2020\/2222788\/blooda_adv-2023-012062-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:20:49Z","timestamp":1713885649000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/2020\/514602\/Guadecitabine-vs-TC-in-relapsed-refractory-AML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012062","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}